We are live on !
Find out more
CCM
Catapult Capital Management Portfolio holdings
AUM
$265M
Turnover
70.98%
1-Year Est. Return
21.83%
This Fund
S&P 500
This Quarter Est. Return
-6.98%
1 Year Est. Return
+21.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$265M
AUM Growth
-$431M
(-62%)
Cap. Flow
-$354M
Cap. Flow % of AUM
Cap. Flow %
-133.94%
Top 10 Holdings %
Top 10 Hldgs %
27.43%
Holding
286
New
68
Increased
19
Reduced
60
Closed
135
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$10M |
| 2 |
NUVA
NuVasive, Inc.
NUVA
|
+$4.39M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$3.85M |
| 4 |
Boston Scientific
BSX
|
+$3.16M |
| 5 |
Pfizer
PFE
|
+$3.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$16M |
| 2 |
AbbVie
ABBV
|
+$15.9M |
| 3 |
Zoetis
ZTS
|
+$13.5M |
| 4 |
PepsiCo
PEP
|
+$12.8M |
| 5 |
McKesson
MCK
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.84% |
| 2 | Miscellaneous | 27.62% |
| 3 | Consumer Discretionary | 8.53% |
| 4 | Industrials | 6.49% |
| 5 | Technology | 4.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $11.6M | 4.37% |
42,500
+32,500
| +325% | +$10M |
2015 Q1
2 quarters
|
|
2
Edwards Lifesciences
EW
$53.9B
| $9.03M | 3.42% |
381,258
-344,460
| -47% | -$8.31M |
2014 Q3
4 quarters
|
|
|
3
Zoetis
ZTS
$33B
| $8.05M | 3.04% |
195,525
-291,140
| -60% | -$13.5M |
2015 Q2
1 quarter
|
|
|
AET
4
DELISTED
Aetna Inc
AET
| $7.97M | 3.01% |
72,877
+22,877
| +46% | +$2.64M |
2015 Q2
1 quarter
|
|
|
CNW
5
PUT
DELISTED
CON-WAY INC.
CNW
| $6.64M | 2.51% |
+140,000
| New | +$5.49M |
2015 Q3
0 quarters
|
|
|
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
| $6.51M | 2.46% |
135,000
+85,000
| +170% | +$4.39M |
2015 Q2
1 quarter
|
|
7
CALL
Bank of America
BAC
$348B
| $6.23M | 2.36% |
+400,000
| New | +$6.73M |
2015 Q3
0 quarters
|
|
8
DaVita
DVA
$11.4B
| $6.14M | 2.32% |
84,938
-90,162
| -51% | -$6.99M |
2013 Q4
7 quarters
|
|
|
9
Boston Scientific
BSX
$62.1B
| $5.5M | 2.08% |
335,000
+185,000
| +123% | +$3.16M |
2015 Q2
1 quarter
|
|
10
AtriCure
ATRC
$3.12B
| $4.93M | 1.86% |
225,000
+15,000
| +7% | +$375K |
2013 Q2
9 quarters
|
|
11
CALL
Magna International
MGA
$17.1B
| $4.8M | 1.81% |
+100,000
| New | +$5.17M |
2015 Q3
0 quarters
|
|
12
Universal Health Services
UHS
$10.4B
| $4.76M | 1.8% |
38,095
-51,905
| -58% | -$7.22M |
2014 Q4
3 quarters
|
|
|
ALR
13
DELISTED
Alere Inc
ALR
| $4.41M | 1.67% |
91,622
+41,622
| +83% | +$2.16M |
2015 Q2
1 quarter
|
|
|
14
CVS Health
CVS
$116B
| $4.36M | 1.65% |
45,172
-151,775
| -77% | -$16M |
2014 Q4
3 quarters
|
|
15
DELISTED
Cross Country Healthcare
CCRN
| $3.74M | 1.41% |
275,000
+25,000
| +10% | +$340K |
2015 Q1
2 quarters
|
|
16
Gilead Sciences
GILD
$214B
| $3.58M | 1.35% |
36,408
-34,392
| -49% | -$3.82M |
2015 Q2
1 quarter
|
|
17
CALL
Agilent Technologies
A
$49.2B
| $3.43M | 1.3% |
100,000
+70,000
| +233% | +$2.65M |
2015 Q2
1 quarter
|
|
18
Align Technology
ALGN
$10.6B
| $3.39M | 1.28% |
59,722
-20,278
| -25% | -$1.21M |
2015 Q2
1 quarter
|
|
|
MNK
19
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $3.2M | 1.21% |
+50,000
| New | +$4.95M |
2015 Q3
0 quarters
|
|
20
CALL
AB InBev
BUD
$158B
| $3.19M | 1.21% |
30,000
+15,000
| +100% | +$1.74M |
2015 Q2
1 quarter
|
|
|
21
Vertex Pharmaceuticals
VRTX
$141B
| $3.12M | 1.18% |
+30,000
| New | +$3.85M |
2015 Q3
0 quarters
|
|
22
McDonald's
MCD
$182B
| $3.06M | 1.15% |
31,007
-35,193
| -53% | -$3.43M |
2015 Q1
2 quarters
|
|
23
PUT
Molson Coors Class B
TAP
$7.47B
| $2.91M | 1.1% |
+35,000
| New | +$2.53M |
2015 Q3
0 quarters
|
|
|
BCR
24
DELISTED
CR Bard Inc.
BCR
| $2.9M | 1.09% |
+15,537
| New | +$2.94M |
2015 Q3
0 quarters
|
|
|
25
Pfizer
PFE
$173B
| $2.82M | 1.07% |
+94,657
| New | +$3.04M |
2015 Q3
0 quarters
|
|
Similar funds
TCOTO
DCM
TFF
Catapult Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Catapult Capital Management held 286 positions worth $265M, down 62% from $696M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Catapult Capital Management withdrew a net $354M in Q3 2015, closing 135 positions and reducing 60 holdings. Its most notable exit was PepsiCo, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
Against the trend, Catapult Capital Management opened a new position in Vertex Pharmaceuticals worth $3.12M.
- Catapult Capital Management's largest Q3 2015 buy was Vertex Pharmaceuticals: 30,000 shares worth $3.12M.
- Catapult Capital Management added most to Allergan plc in Q3 2015, an estimated $10M increase.
- Catapult Capital Management's biggest Q3 2015 reduction was CVS Health, cutting an estimated $16M.
- Catapult Capital Management fully exited PepsiCo in Q3 2015, selling an estimated $12.8M.
- Catapult Capital Management's ten largest holdings make up 27% of its $265M portfolio in Q3 2015.
- Catapult Capital Management opened 68 new positions and closed 135 in Q3 2015.
- Catapult Capital Management's portfolio value fell 62% quarter-over-quarter to $265M.
Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.